Latest Financing News

GenusPlus Group Ltd has reported a record half-year with a 61% jump in revenue to $535.4 million and an 82% rise in net profit to $24.9 million, driven by strong performance across all business segments and strategic acquisitions. The company also declared its first-ever fully franked interim dividend of 2.0 cents per share.

Hartshead Resources has updated the schedule for its proposed acquisition by ACAM GP Limited, with key shareholder and court dates set through May 2026. The revised timetable outlines the next steps in the scheme of arrangement process.

Alfabs Australia reported a 28% revenue rise to $55.6 million in H1 2026, but EBITDA fell due to a $2.8 million Dartbrook mine impact and softer engineering margins. The company is investing heavily in mining hire assets and pursuing a strategic acquisition to drive future growth.

Liberty Financial Group has reported a robust 12% increase in underlying NPATA to $82.3 million for the half year ending December 2025, supported by record loan originations and a strong balance sheet. The acquisition of Moula is set to accelerate unsecured SME lending, while cost efficiencies and moderating credit risk underpin improved financial metrics.

Cash Converters International Limited reported an 8% rise in half-year revenue to $206.7 million, driven by franchise acquisitions and a shift in lending strategy. Despite a 17% dip in net profit due to one-off costs, the company declared a fully franked interim dividend and reinstated its Dividend Reinvestment Plan.

McMillan Shakespeare Limited reported a 9.7% rise in statutory net profit for the first half of FY26, driven by strong revenue growth and productivity gains. The company declared a fully franked 62 cent dividend and announced a $10 million on-market share buyback.

Cash Converters International Limited has announced the recommencement of its Dividend Reinvestment Plan (DRP) effective 20 February 2026, restoring shareholders’ ability to reinvest dividends into additional shares with favourable terms.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

MyState Limited reported a robust half-year result with a 61% rise in underlying net profit, driven by the full impact of its Auswide Bank merger and strong growth across key business lines. The company also declared a fully franked interim dividend of 12 cents per share.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.

Newmont Corporation’s 2025 Annual Report reveals a robust financial performance driven by higher gold prices and portfolio optimisation, alongside significant progress in key development projects and sustainability initiatives.